aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression
January 25, 2021 08:00 ET
|
aTyr Pharma, Inc.
Poster highlights NRP2 expression on immune cells in the tumor microenvironment. Company's lead NRP2 antibody, ATYR2810, is in development for oncology. SAN DIEGO, Jan. 25, 2021 ...
aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases
January 22, 2021 08:00 ET
|
aTyr Pharma, Inc.
Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. Research approach led to the identification of target receptors for...
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan
January 14, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Writer Shares Invaluable Tips for Navigating Womanhood and Life in Humorous and Reflective New Book
January 12, 2021 09:00 ET
|
Archway Publishing
NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- As another year passes by, an opportunity to contemplate life arises. As Christine R. Andola celebrated her 40th birthday, she became more in tune with...
Decision Strategy Innovator Provides Tips on Self-trust, Resilience and Potentials for Triumph in her new Self-Help/Business Book
January 11, 2021 21:00 ET
|
Balboa Press
ALBUQUERQUE, N.M., Jan. 11, 2021 (GLOBE NEWSWIRE) -- While sharing stories of her personal and professional journey through life and its twists and turns, author of “How The Tin Man Found His Brain:...
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
January 07, 2021 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
January 04, 2021 16:15 ET
|
aTyr Pharma, Inc.
Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients. A single dose of 3.0 mg/kg of ATYR1923 resulted in a median time to recovery of 5.5 days. 83% of patients...
aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
December 21, 2020 07:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
November 12, 2020 16:05 ET
|
aTyr Pharma, Inc.
Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational New Drug...
aTyr Pharma Announces Publication in the Journal mAbs
November 11, 2020 07:00 ET
|
aTyr Pharma, Inc.
Peer-reviewed paper supports aTyr’s antibody program. Research conducted in collaboration with AbCellera Biologics, Inc. SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:...